Antiviral Drugs - Worldwide

Worldwide

The projected revenue in the Antiviral Drugs market worldwide is estimated to reach €46.97bn in 2024.
It is expected to exhibit an annual growth rate (CAGR 2024-2029) of 1.42%, leading to a market volume of €50.41bn by 2029.
In terms of global comparison, United States is anticipated to generate the highest revenue, with €28,120.00m in 2024.
In the worldwide market for antiviral drugs, the United States leads in research and development, driving innovation and setting industry standards.

Key regions: Brazil, India, Australia, United States, United Kingdom

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for antiviral drugs has been increasing globally due to the growing prevalence of viral diseases.

Customer preferences: Customers are increasingly seeking antiviral drugs that are effective against a wide range of viruses and have minimal side effects. They also prefer drugs that are easy to administer and have a shorter treatment duration.

Trends in the market: The Antiviral Drugs segment is expected to experience significant growth, which is mainly driven by the testing of novel treatments for COVID-19. There are also more general drivers of the market: the rising number of HIV cases worldwide and the need for continuous development in the field of antiviral drugs as it is in the nature of viruses to mutate and thus to increase their tolerance to drugs. Growing revenues generated by drugs with active patents and the counteracting decline in the case of other drugs which face competition result in stagnant growth. Within the antiviral drugs market, the largest area is HIV. In parts of the world, antiviral drugs have succeeded in keeping HIV a chronic condition without its progressing to AIDS. For hepatitis C, the number of new patients is shrinking in the U.S. and in Europe. Due to the COVID-19 pandemic, fewer new patients decided to seek medical treatment, leading to a certain decline in the revenue of HIV drugs.

Local special circumstances: In China, the antiviral drugs market is expected to grow due to the government's efforts to improve healthcare infrastructure and increase access to medicines. The market in India is being driven by the growing prevalence of HIV and the increasing government initiatives to tackle the disease.

Underlying macroeconomic factors: The global antiviral drugs market is being driven by factors such as the increasing prevalence of viral diseases, the growing geriatric population, and the rising demand for antiviral drugs in emerging economies. However, factors such as the high cost of antiviral drugs and the increasing prevalence of drug-resistant viruses are likely to hamper market growth.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.